Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial

NCT07274384 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)
Hyperprogression

Interventions

COMBINATION_PRODUCT: chemotherapy plus cemiplimab
DRUG: Cemiplimab

Sponsor

Università Vita-Salute San Raffaele

Collaborators

[object Object]